Vertex, Mammoth partner to develop in vivo gene-editing therapies
Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.
📰 Peter Nell News
Page 2 - Peter Nell News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Nell. Real-time updates on events, politics, business and more.
Vertex, Mammoth Launch Up-to-$695M CRISPR Gene-Editing Collaboration
Vertex Pharmaceuticals will develop in vivo gene-editing therapies for two genetic diseases using Mammoth Biosciences’ CRISPR systems through a collaboration that could generate more than $695 million for Mammoth.
Source: genengnews.com